Background: It has been hypothesized that genomic instability related to telomere dysfunction may contribute to carcinogenesis. There is some evidence from case-control studies suggesting that short leukocyte telomere length may be associated with an increased risk of renal cell carcinoma (RCC); however, this association has not been investigated prospectively.
Introduction
Telomeres, nucleotide repeats at chromosome ends, are essential for chromosomal stability. Telomeres become gradually shorter with each cell division due to inefficient replication at the ends of linear DNA. Although critically short telomeres trigger cellular senescence and death in normal cells, cancer cells continue to divide despite the resultant genomic instability. Telomere length in peripheral blood leukocytes is a suspected marker of cancer risk (1) . Results of retrospective case-control studies of leukocyte telomere length and renal cell carcinoma (RCC) have been inconsistent; 2 small hospital-based studies reported inverse associations between telomere length and RCC (2, 3), whereas no association was observed in a large population-based study (4) . To our knowledge, this association has not been investigated prospectively. To address this research gap, we evaluated RCC risk in relation to prediagnostic leukocyte telomere length in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Materials and Methods
Enrollment and specimen collection procedures in PLCO have been described in ref. (5) . Briefly, 155,000 subjects between 55 and 74 years of age were enrolled through study centers in 10 U.S. cities between 1993 and 2001. Half of the subjects were randomized to the screening arm of the trial and provided nonfasting blood samples at 6 annual screening examinations for trial disease outcomes. In addition to the annual examinations, questionnaires were mailed to subjects annually to ascertain new cancer diagnoses, which were pathologically confirmed through medical record abstraction. The trial was approved by Institutional Review Boards at the National Cancer Institute and the 10 study centers, and all subjects provided written informed consent.
We measured leukocyte telomere length in 209 histologically confirmed cases of RCC (ICD-O-2 C64.9) and 410 controls individually matched to each case by sex, baseline age (5-year categories), race (white, black, other), date of phlebotomy (4-month categories), and study year of blood collection. DNA was extracted from buffy coat using QIAamp DNA Blood Maxi Kits (Qiagen Inc.). Methods for telomere length assays have been described (6) . Briefly, telomere repeat (T) and single gene (S) copy numbers were measured in each sample and adjusted in comparison with standard reference DNA; the standardized T:S ratio characterizes relative telomere length. Samples were assayed in triplicate and the average T:S ratio was calculated. Samples for each case and the corresponding matched controls were analyzed consecutively on the same plate. The within-plate coefficient of variation (from 36 blinded quality control samples distributed evenly across 9 plates) was 5.9%. ORs and 95% confidence intervals (CI) were estimated using conditional logistic regression. Our study had 85% power to detect an OR of 0.5 (or 2.0) comparing the highest and lowest quartiles of telomere length. All analyses were conditioned on matched sets, and analyses further adjusted for body mass index (BMI), history of hypertension, and smoking status (never, former, and current) were conducted. We also conducted analyses stratified by sex, age at blood collection (55-64 years, 65-74 years), and time from blood collection to RCC diagnosis (<6 years, 6 years).
Results
Cases and controls had similar distributions of age, sex, and race (Table 1) . Cases were more likely than controls to be obese and to have a history of hypertension. The proportion of never-smokers was slightly higher among controls. Among controls, we observed shorter telomere length among subjects who were older, male, nonHispanic white, obese, and current smokers (Supplementary Table S1 ).
Prediagnostic leukocyte telomere length was not significantly associated with RCC (Table 2) . Risk estimates did not differ by sex, age at blood collection, or time from blood collection to RCC diagnosis ( Table 2) . We did not observe differences by tumor grade or after restricting to clear cell RCC cases (N cases ¼ 192; data not shown).
Discussion
This study is, to our knowledge, the first prospective investigation of leukocyte telomere length and RCC. Although short leukocyte telomere length was associated with increased RCC risk in 2 small hospital-based case-control studies (32 and 65 cases, respectively; refs. 2, 3), no association was observed in a larger population-based case-control study (891 cases; ref.
4).
Risk estimates for various malignancies have been inconsistent between prospective and retrospective studies (1); although short telomere length seems to be associated with cancer in studies conducted retrospectively, those conducted prospectively have generally found either no association or, for non-Hodgkin lymphoma and lung cancer, increased risk with longer telomere length (7, 8) .
In summary, our prospective study was sufficiently powered to detect an association smaller in magnitude than what has been reported in previous retrospective studies [e.g., OR ¼ 5.4 comparing the lowest and highest quartiles in ref. (3)]. However, we found no evidence of association between prediagnostic leukocyte telomere length and RCC risk, suggesting that leukocyte telomere length is not a biomarker of risk related to the etiology of RCC. Tests for trend were conducted by assigning the within-category median for each quartile and analyzing these data as a continuous variable. c Conditioned on matched sets.
